+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alport Syndrome - Epidemiology Forecast - 2028

  • ID: 4855551
  • Report
  • November 2019
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 2
“Alport Syndrome -Epidemiology Forecast-2028” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Alport syndrome in Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

Geography Covered
  • Turkey
  • Russia
  • Colombia
  • Brazil
  • Argentina
  • Mexico
  • Saudi Arabia
  • UAE
  • Taiwan
  • China
Study Period: 2017-2028

Alport Syndrome - Epidemiology

The Alport syndrome epidemiology division provides the insights about historical and current patient pool and forecasted trend for all ten emerging market. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the total disease prevalence, diagnosed cases, treatable cases and prevalence based on clinical types and clinical manifestations in Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed cases and total treatable cases) scenario of Alport syndrome in the ten emerging markets, i.e., Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China from 2017-2028.

According to this research, total prevalent population of Alport syndrome in ten emerging markets was found to be 187,718 in 2017.

Alport syndrome Report Insights
  • The report covers detailed overview of Alport syndrome explaining its causes, symptoms, and pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for ten emerging market i.e. Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan, and China.
  • The Report highlights the unmet needs of Alport syndrome.
  • The Report helps to recognize the growth opportunities in the ten emerging markets with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total prevalent population, diagnosed cases, treatable cases and clinical types and clinical manifestations specific prevalent population in ten emerging market.
Alport syndrome Report Key Strengths
  • 10 Year Forecast
  • 10 emerging market Coverage
  • Prevalent cases
  • Diagnosed cases
  • Treatable cases
  • Clinical types specific prevalent population
  • Clinical manifestations specific prevalent population
Alport syndrome Report Assessment
  • Patient Segmentation
  • Disease Risk & Burden
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Alport Syndrome: Epidemiology Overview at a Glance
2.1. Total Prevalent Population of Alport Syndrome in 2017
2.2. Total Prevalent Population of Alport Syndrome in 2028

3. Alport Syndrome: Disease Background and Overview
3.1. Introduction
3.2. Causes and Risk Factors
3.3. Inheritance Pattern
3.4. Signs and Symptoms
3.5. Clinical Manifestations
3.5.1. Renal Manifestations
3.5.2. Audiological Manifestations
3.5.3. Ophthalmological Manifestations
3.6. Pathophysiology
3.7. Diagnostic Approach

4. Treatment
4.1. Current treatment for Alport Syndrome
4.2. Future treatment for Alport Syndrome
4.3. Treatment Algorithm

5. Unmet Needs

6. Organizations contributing toward Alport Syndrome

7. KOL's Views: Alport Syndrome

8. Key Cross Competitors

9. Marketed Drugs
9.1. Bardoxolone Methyl: Reata Pharmaceuticals
9.1.1. Product Description
9.1.2. Clinical Development
9.1.3. Other Development Activities
9.1.4. Product Profile
9.2. RG 012/ SAR339375: Sanofi
9.2.1. Product Description
9.2.2. Clinical Development
9.2.3. Other Development Activities
9.2.4. Product Profile

10. Case Reports
10.1. A Novel COL4A3 Mutation Causes Autosomal-Recessive Alport Syndrome in a Large Turkish Family
10.2. Alport-like glomerular changes in a patient with nephrotic syndrome: report of a case
10.3. Alport Syndrome with Recurrent Herpes Simplex Virus Keratitis
10.4. Russian Family with X-linked Alport Syndrome and Cardiovascular Abnormalities
10.5. An overlap of Alport syndrome and rheumatoid arthritis in a patient and literature review
10.6. Macular Hole Surgery in Alport Syndrome
10.7. Female Patient with Alport Syndrome and Concomitant Membranous Nephropathy: Susceptibility or Association of Two Diseases?
10.8. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
10.9. Nephropathies with a pattern of structural alterations of the glomerular basement membrane: Case study

11. Epidemiology and Patient Population
11.1. Key Findings

12. Emerging Markets Total Prevalent Population of Alport Syndrome

13. Country Wise-Epidemiology of Alport Syndrome
13.1. Assumptions and Rationale
13.2. Latin America
13.2.1. Argentina
13.2.2. Brazil
13.2.3. Colombia
13.2.4. Mexico
13.3. Middle East and Europe
13.3.1. Russia
13.3.2. Saudi Arabia
13.3.3. Turkey
13.3.4. United Arab Emirates (UAE)
13.4. Asia
13.4.1. China
13.4.2. Taiwan

14. Market Drivers

15. Market Barriers

16. Appendix

17. Capabilities

18. Disclaimer

19. About the Publisher

List of Tables
Table 1: List of drugs for the treatment of Alport syndrome
Table 2: Organizations contributing toward Alport Syndrome
Table 3: Key Cross Competitors
Table 4: Bardoxolone Methyl, Clinical Trial Description, 2019
Table 5: Bardoxolone Methyl, Safety and Efficacy Description
Table 6: Bardoxolone Methyl, Drug Profile
Table 7: RG 012, Clinical Trial Description, 2019
Table 8: RG012, Preclinical Results
Table 9: RG 012, Drug Profile
Table 10: Total Prevalent Patient Population of Alport Syndrome in 10 emerging markets (2017-2028)
Table 11: Total Prevalent Population of Alport Syndrome in Argentina (2017-2028)
Table 12: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Argentina (2017-2028)
Table 13: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Argentina (2017-2028)
: Diagnosed cases of Alport Syndrome in Argentina (2017-2028)
Table 14: Treatable cases of Alport Syndrome in Argentina (2017-2028)
Table 15: Total Prevalent Population of Alport Syndrome in Brazil (2017-2028)
Table 16: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Brazil (2017-2028)
Table 17 : Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Brazil (2017-2028)
Table 18: Diagnosed cases of Alport Syndrome in Brazil (2017-2028)
Table 19: Treatable cases of Alport Syndrome in Brazil (2017-2028)
Table 20: Total Prevalent Population of Alport Syndrome in Colombia (2017-2028)
Table 21: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Colombia (2017-2028)
Table 22: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Colombia (2017-2028)
Table 23: Diagnosed cases of Alport Syndrome in Colombia (2017-2028)
: Treatable cases of Alport Syndrome in Colombia (2017-2028)
Table 24: Total Prevalent Population of Alport Syndrome in Mexico (2017-2028)
Table 25: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Mexico (2017-2028)
Table 26: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Mexico (2017-2028)
Table 27: Diagnosed cases of Alport Syndrome in Mexico (2017-2028)
Table 28: Treatable cases of Alport Syndrome in Mexico (2017-2028)
Table 29: Total Prevalent Population of Alport Syndrome in Russia (2017-2028)
Table 30: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Russia (2017-2028)
Table 31: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Russia (2017-2028)
Table 32: Diagnosed cases of Alport Syndrome in Russia (2017-2028)
Table 33: Treatable cases of Alport Syndrome in Russia (2017-2028)
Table 34: Total Prevalent Population of Alport Syndrome in Saudi Arabia (2017-2028)
Table 35: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Saudi Arabia (2017-2028)
Table 36: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Saudi Arabia (2017-2028)
Table 37: Diagnosed cases of Alport Syndrome in Saudi Arabia (2017-2028)
Table 38: Treatable cases of Alport Syndrome in Saudi Arabia (2017-2028)
: Total Prevalent Population of Alport Syndrome in Turkey (2017-2028)
Table 39: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Turkey (2017-2028)
Table 40: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Turkey (2017-2028)
Table 41: Diagnosed cases of Alport Syndrome in Turkey (2017-2028)
Table 42: Treatable cases of Alport Syndrome in Turkey (2017-2028)
Table 43: Total Prevalent Population of Alport Syndrome in UAE (2017-2028)
Table 44: Total Prevalent Population Based on Clinical Types of Alport Syndrome in UAE (2017-2028)
Table 45: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in UAE (2017-2028)
Table 46: Diagnosed cases of Alport Syndrome in UAE (2017-2028)
Table 47: Treatable cases of Alport Syndrome in UAE (2017-2028)
Table 48: Total Prevalent Population of Alport Syndrome in China (2017-2028)
Table 49: Total Prevalent Population Based on Clinical Types of Alport Syndrome in China (2017-2028)
Table 50: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in China (2017-2028)
Table 51: Diagnosed cases of Alport Syndrome in China (2017-2028)C
Table 52: Treatable cases of Alport Syndrome in China (2017-2028)
Table 53: Total Prevalent Population of Alport Syndrome in Taiwan (2017-2028)
Table 54: Total Prevalent Population Based on Clinical Types of Alport Syndrome in Taiwan (2017-2028)
Table 55: Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Taiwan (2017-2028)
Table 56: Diagnosed cases of Alport Syndrome in Taiwan (2017-2028)
Table 57: Treatable cases of Alport Syndrome in Taiwan (2017-2028)

List of Figures
Figure 1 Total Prevalent Population of Alport Syndrome in the emerging markets (2017)
Figure 2 Total Prevalent Population of Alport Syndrome in the emerging markets (2028)
Figure 3 A frozen human kidney section stained in red for COL4A4, representing the a-3 a-4 a-5(IV) network
Figure 4 XLAS inheritance pattern (affected father)
Figure 5 XLAS inheritance pattern (affected mother)
Figure 6 ARAS inheritance pattern
Figure 7 ADAS inheritance pattern
Figure 8 Clinical manifestations
Figure 9 Clinical presentation in Alport syndrome and the potential effect of treatment
Figure 10 Fundus examination of the eye demonstrating peri-macular flecks
Figure 11 Vesicle-like lesions in PPCD
Figure 12 Normal and Alport glomerular filtration barriers
Figure 13 Potential mechanisms underlying chronic renal disease occurring in Alport syndrome
Figure 14 Indications for genetic testing in Alport syndrome
Figure 15 An approach to diagnose Alport syndrome
Figure 16 Medications for Alport Syndrome
Figure 17 Therapeutic targets in Alport syndrome
Figure 18 Treatment Algorithm for Alport Syndrome
Figure 19 Unmet Needs of Alport Syndrome
Figure 20 Mechanism of action of Bardoxolone Methyl
Figure 21 Study Design: CARDINAL
Figure 22 Mechanism of action of RG 012
Figure 23 Total Prevalent Population of Alport Syndrome in 10 emerging markets (2017-2028)
Figure 24 Total Prevalent Population of Alport Syndrome in Argentina (2017-2028)
Figure 25 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Argentina (2017-2028)
Figure 26 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Argentina (2017-2028)
Figure 27 Diagnosed Cases of Alport Syndrome in Argentina (2017-2028)
Figure 28 Treatable Cases of Alport Syndrome in Argentina (2017-2028)
Figure 29 Total Prevalent Population of Alport Syndrome in Brazil (2017-2028)
Figure 30 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Brazil (2017-2028)
Figure 31 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Brazil (2017-2028)
Figure 32 Diagnosed Cases of Alport Syndrome in Brazil (2017-2028)
Figure 33 Treatable Cases of Alport Syndrome in Brazil (2017-2028)
Figure 34 Total Prevalent Population of Alport Syndrome in Colombia (2017-2028)
Figure 35 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Colombia (2017-2028)
Figure 36 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Colombia (2017-2028)
Figure 37 Diagnosed Cases of Alport Syndrome in Colombia (2017-2028)
Figure 38 Treatable Cases of Alport Syndrome in Colombia (2017-2028)
Figure 39 Total Prevalent Population of Alport Syndrome in Mexico (2017-2028)
Figure 40 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Mexico (2017-2028)
Figure 41 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Mexico (2017-2028)
Figure 42 Diagnosed Cases of Alport Syndrome in Mexico (2017-2028)
Figure 43 Treatable Cases of Alport Syndrome in Mexico (2017-2028)
Figure 44 Total Prevalent Patient Population of Alport Syndrome in Russia (2017-2028)
Figure 45 Total Prevalent Patient Population Based on Clinical Types of Alport Syndrome in Russia (2017-2028)
Figure 46 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Russia (2017-2028)
Figure 47 Diagnosed Cases of Alport Syndrome in Russia (2017-2028)
Figure 48 Treatable Cases of Alport Syndrome in Russia (2017-2028)
Figure 49 Total Prevalent Population of Alport Syndrome in Saudi Arabia (2017-2028)
Figure 50 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Saudi Arabia (2017-2028)
Figure 51 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Saudi Arabia (2017-2028)
Figure 52 Diagnosed Cases of Alport Syndrome in Saudi Arabia (2017-2028)
Figure 53 Treatable Cases of Alport Syndrome in Saudi Arabia (2017-2028)
Figure 54 Total Prevalent Population of Alport Syndrome in Turkey (2017-2028)
Figure 55 Total Prevalent Population Based on Clinical Types of Alport Syndrome in Turkey (2017-2028)
Figure 56 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Turkey (2017-2028)
Figure 57 Diagnosed Cases of Alport Syndrome in Turkey (2017-2028)
Figure 58 Treatable Cases of Alport Syndrome in Turkey (2017-2028)
Figure 59 Total Prevalent Population of Alport Syndrome in UAE (2017-2028)
Figure 60 Total Prevalent Population Based on Clinical Types of Alport Syndrome in the UAE (2017-2028)
Figure 61 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in the UAE (2017-2028)
Figure 62 Diagnosed Cases of Alport Syndrome in the UAE (2017-2028)
Figure 63 Treatable Cases of Alport Syndrome in the UAE (2017-2028)
Figure 64 Total Prevalent Population of Alport Syndrome in China (2017-2028)
Figure 65 Total Prevalent Population Based on Clinical Types of Alport Syndrome in China (2017-2028)
Figure 66
Figure 67
Figure 68
Figure 69
Figure 70
Figure 71
Figure 72
Figure 73
Figure 74
Figure 75 Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in China (2017-2028)
Diagnosed Cases of Alport Syndrome in China (2017-2028)
Treatable Cases of Alport Syndrome in China (2017-2028)
Total Prevalent Population of Alport Syndrome in Taiwan (2017-2028)
Total Prevalent Population Based on Clinical Types of Alport Syndrome in Taiwan (2017-2028)
Total Prevalent Population Based on Clinical Manifestations of Alport Syndrome in Taiwan (2017-2028)
Diagnosed Cases of Alport Syndrome in Taiwan (2017-2028)
Treatable Cases of Alport Syndrome in Taiwan (2017-2028)
Market Drivers
Market Barriers
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll